Bio-techne Corp · NASDAQ:TECH

Bio-techne — Investor Presentation (June 2025)

15 slides from Bio-techne's investor presentation, Jun 3, 2025

1. Slide 1: Purposeful Innovation Leads to Better Answers

   Purposeful Innovation Leads to Better Answers Kim Kelderman President & CEO June 3, 2025 © 2025 Bio-Techne®. All rights reserved. | 1

2. Slide 2: Safe Harbor Cautionary Statements

   Safe Harbor CAUTIONARY STATEMENTS This presentation contains “forward-looking Forward-looking statements are neither historical looking statement, whether written or oral, as statements” within the meaning of the federal facts nor assurances of future performance. a result of new information, future

3. Slide 3: © 2025 Bio-Techne ® . All rights reserved. | 3

   © 2025 Bio-Techne®. All rights reserved. | 3

4. Slide 4: Differentiated Portfolio Serving High-Growth Markets

   48-YEAR LEADER IN PROTEOMICS Differentiated Portfolio Headquarters Minneapolis, MN Serving High-Growth Markets Number of Employees Our Segments and Product Portfolio ~3,100 Instruments Services Protein Sciences: 9% 9% Royalties Worldwide Locations 2% 34 Instrument specific Proteins Antibodies Immuno

5. Slide 5: FY24 Revenue Breakdown ($1.2B)

   FY24 Revenue Breakdown ($1.2B) Markets 12% Distributors Segments & Product End Markets 17% 50% Diagnostics Pharma/ 72% Protein Sciences Segment 28% Diagnostics & Spatial Biology Segment Biotech 21% Academia Spatial Biology 10% Precision Diagnostic 6% Tools Core Diagnostic Geographies Core RUO 12% Co

6. Slide 6: Foundation For Our Success

   Durable and differentiated product portfolio Balanced exposure to established and emerging applications across high-growth end-markets Foundation For Our Portfolio leverage from leading protein & antibody content and capabilities Success Strong reputation and loyal customer base valuing quality and

7. Slide 7: Our Growth Vectors Capitalize on Megatrends

   Our Growth Strategic Growth Vectors: Vectors Healthy 3 Enablement of Capitalize on Precision Aging Diagnostics Megatrends Precision Medicine Novel Therapeutic Approaches Development and 2 Manufacturing of Advanced AI-enabled Innovation Therapeutics Proteomic Interrogation at Scale Multiomic Insight

8. Slide 8: Differentiated Product Portfolio Creates Leverage

   Differentiated Product Portfolio Creates Leverage Product Portfolio Our Strategic Growth Vectors Protein Sciences 1 Discovery of Novel Biological Insights Antibodies Proteomic Spatial Analytical Biology Proteins Antibodies Immunoassays Proteins & Small Instruments Molecules Immunoassays Proteomic Ce

9. Slide 9: Innovation Milestones in Our Growth Vectors

   Innovation Milestones in Our Growth Vectors 1 2 3 Discovery of Novel Biological Insights Development & Manufacturing Enablement of of Advanced Therapeutics Precision Diagnostics Leo™ AI Designed Multiomic Spatial ProPak™ GMP ESR1 Instrument Reagents Biology Platform Reagents Kit Next-generation, Pip

10. Slide 10: Driving Growth Despite Market Volatility

    Driving Growth Despite Market Volatility Revenue ($M) Adj. Operating Income ($M) +1% OG -10% 410 1,137 1,159 370 12% 14% +6% OG CAGR +5% CAGR 903 282 853 268 244 714 FY19 FY23 FY24 Q1-Q3 Q1-Q3 FY19 FY23 FY24 Q1-Q3 Q1-Q3 FY24 FY25 FY24 FY25 © 2025 Bio-Techne®. All rights reserved. | 10

11. Slide 11: Strong Programmatic M&A Runway

    Strong Programmatic M&A Runway Growth Vectors M&A Priorities • Analytical platforms Discovery of Novel • Product tuck-ins, applications expansions 11 Biological • Targeted innovation capabilities Insights • Opportunistic expansion Development & Manufacturing • Cell therapy workflow components and so

12. Slide 12: Portfolio Serves Critical Applications Within $28B Market

    Portfolio Serves Critical Applications Within $28B Market DIAGNOSTICS & SPATIAL BIOLOGY SEGMENT Proteomic Analytics Spatial Biology PROTEIN SCIENCES SEGMENT Market Size Market Size Market Growth Rate Core Products Market Growth Rate Research Reagents, Assays & Dx Controls Historic 5-yr Historic 5-yr

13. Slide 13: We are Committed to a Sustainable Future

    We are Committed to a Sustainable Future PUBLISHED OUR FOURTH CORPORATE SUSTAINABILITY REPORT Our People Advancing Science 43% female supervisor ~800 new products in 2024 & above globally ~8% of revenue invested in R&D Diverse and Inclusive 11 active Employee Resource workplace Groups (ERGs) The Env

14. Slide 14: Key Takeaways

    Key Takeaways The shown Megatrends create a flywheel for our three Strategic Growth Vectors Our differentiated proteomic core portfolio provides leverage across these Strategic Growth Vectors Together, We have a strong innovation and M&A pipeline to we unlock the expand portfolio and market position

15. Slide 15: © 2025 Bio-Techne ® . All rights reserved. | 15

    © 2025 Bio-Techne®. All rights reserved. | 15

Bio-Techne — Investor Presentation (June 2025) on 6ix